

#4

**Patent**

Docket Number: AM-00105.P.1.1-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	
	)	
Divita et al.	)	Examiner: To be determined
	)	
Application No.: 09/915,914	)	Art Unit: To be determined
	)	
Filed: July 26, 2001	)	
	)	
For: PEPTIDE-MEDIATED	)	
DELIVERY OF MOLECULES	)	
INTO CELLS	)	
	)	

Assistant Commissioner for Patents  
Washington D.C. 20231


Sir:

STATEMENT UNDER 37 C.F.R. 1.821 - 1.825

In accordance with the requirements under 37 C.F.R. 1.821 through 1.825 for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, Applicants submit herewith a Substitute Sequence Listing and corresponding Computer-Readable Sequence Listing for the above-identified application. The contents of the enclosed Substitute Sequence Listing and Computer-Readable Sequence Listing are identical. Support for the sequence in the Substitute Sequence Listing can be found in the Sequence Listing as filed with the above-identified application on July 26, 2001. No substantive changes to the Sequence Listing have been made. Thus, the substitute Sequence Listing and Computer-Readable Sequence Listing include no new matter.

Date: October 17, 2001

Respectfully submitted,



David R. Preston

Reg. No. 38,710

David R. Preston & Associates  
12625 High Bluff Drive  
Suite 205  
San Diego, CA 92130  
858.724.0375



**Patent**

Docket Number: AM-00105.P.1.1-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Divita et al.

Application No.: 09/915,914

Filed: July 26, 2001

For: PEPTIDE-MEDIATED  
DELIVERY OF MOLECULES  
INTO CELLS

Examiner: To be determined

Art Unit: To be determined

Assistant Commissioner for Patents  
Washington D.C. 20231


Sir:

LETTER TO THE COMMISSIONER UNDER 37 C.F.R. 1.821 - 1.825

In accordance with the requirements of 37 C.F.R. 1.821 - 1.825, Applicants submit herewith a substitute Sequence Listing, a Sequence Listing in computer-readable form in accordance with 37 C.F.R. 1.825(b) and a statement under 37 C.F.R. 1.821 - 1.825 that the substitute Sequence Listing and its corresponding computer-readable form are identical, that provides support for the substitute Sequence Listing and that both the substitute Sequence Listing and its corresponding computer-readable form include no new matter. Thus, Applicants have fully met the requirements of 37 C.F.R. 1.821 - 1.825 for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. This submission is being made within one month or thirty days from September 28, 2001, the mailing date of the Office Communication. Thus no extensions of time are deemed necessary.

Respectfully submitted,

Date: October 17, 2001

A handwritten signature in black ink, appearing to read 'David R. Preston', written over a horizontal line.

David R. Preston

Reg. No. 38,710

David R. Preston & Associates  
12625 High Bluff Drive  
Suite 205  
San Diego, CA 92130  
858.724.0375